Sarecycline approved for moderate to severe acne
The US Food and Drug Administration (FDA) has approved sarecycline (Seysara, Almirall) for patients aged 9 years and older with inflammatory lesions associated with non-nodular moderate to severe acne vulgaris. It is a new first-in-class tetracycline-derived oral antibiotic and the first one specifically designed for dermatologic use in more than four decades.
To continue reading this article
Continue reading your article with a eMediNexus account.